Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H2H8

UPID:
PPIL3_HUMAN

ALTERNATIVE NAMES:
Cyclophilin J; Cyclophilin-like protein PPIL3; Rotamase PPIL3

ALTERNATIVE UPACC:
Q9H2H8; Q86WF9; Q96IA9; Q9BXZ1

BACKGROUND:
The enzyme Peptidyl-prolyl cis-trans isomerase-like 3, alternatively named Cyclophilin J, Cyclophilin-like protein PPIL3, or Rotamase PPIL3, is integral to the protein folding process. It facilitates the cis-trans isomerization of proline imidic peptide bonds within oligopeptides, a critical step for achieving the correct protein conformation. Additionally, its potential involvement in pre-mRNA splicing highlights its importance in cellular mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Peptidyl-prolyl cis-trans isomerase-like 3 offers a promising avenue for developing novel therapeutic approaches. Given its essential role in protein folding and potential impact on pre-mRNA splicing, targeting this enzyme could lead to breakthroughs in treating conditions linked to protein misfolding or splicing abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.